The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A composition comprising

a component A comprising one or more compounds that are methyl or methylene donors, wherein the one or more compounds that are methyl or methylene donors comprise one or more compounds selected from the group consisting of betaine, dimethylglycine, sarcosine and serine, and a physiologically acceptable salt thereof,

a component B comprising one or more methyl transporters, wherein the one or more methyl transporters comprise one or more compounds selected from the group consisting of dihydrofolic acid, tetrahydrofolic acid, 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid, 10-formyltetrahydrofolic acid, 5,10-methylenetetrahydrofolic acid, and 5,10-methenyltetrahydrofolic acid, and physiologically acceptable salt thereof, and

a component C comprising one or more bioflavonoids, wherein the one or more bioflavonoids C comprise one or more compounds selected from the group consisting of mono-, di- and triglycoside bioflavonoids that contain an aglycone quercetin.

2. (Currently cancelled without prejudice or disclaimer)

3. (Currently cancelled without prejudice or disclaimer)

4. (Currently Amended) A composition according to claim 1 ~~3~~, wherein component B comprises L-5-methyltetrahydrofolic acid or a physiologically acceptable salt thereof.

5. (Currently cancelled without prejudice or disclaimer)

6. (Currently Amended) A composition according to claim 1 ~~5~~, wherein component C comprises one or more compounds selected from the group consisting of

isoquercetin, quercetin, isoquercitrin, quercimeritrin, spiraeosid, rutin, and hyperin.

7. (Previously Amended) A method of treating or preventing a transmethylation disorder comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

8. (Previously Amended) A method of treating or preventing a cardiovascular disease comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

9. (Previously Amended) A method of treating or preventing an atherogenic and/or thrombogenic disease comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

10. (Previously Amended) A method of treating or preventing a disease associated with hyperhomocysteinemia comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

11. (Previously Amended) A method of treating or preventing premature occlusive arterial disease, severe vascular disease in infancy and childhood, progressive arterial stenosis, intermittent claudication, renovascular hypertension, ischemic cerebrovascular disease, premature retinal artery and retinal vein occlusion, cerebral occlusive arterial disease, occlusive peripheral arterial disease, premature death due to thromboembolic disease and/or ischemic heart disease, comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

12. (Previously cancelled)

13. (Previously Added) A method of preparing a composition according to claim 1, comprising combining components A, B and C.

14. (Previously Added) A composition according to claim 1 further comprising one or more nutritional substances, and/or one or more solid, liquid and/or semi liquid excipients or auxiliaries.

15. (Currently Amended) A food or food supplement comprising ~~a composition according to claim 1~~

a component A comprising one or more compounds that are methyl or methylene donors, wherein the one or more compounds that are methyl or methylene donors comprise one or more compounds selected from the group consisting of betaine, dimethylglycine, sarcosine and serine, and a physiologically acceptable salt thereof,

a component B comprising one or more methyl transporters, wherein the one or more methyl transporters comprise one or more compounds selected from the group consisting of dihydrofolic acid, tetrahydrofolic acid, 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid, 10-formyltetrahydrofolic acid, 5,10-methylenetetrahydrofolic acid, and 5,10-methenyltetrahydrofolic acid, and physiologically acceptable salt thereof, and

a component C comprising one or more bioflavonoids, wherein the one or more bioflavonoids C comprise one or more compounds selected from the group consisting of mono-, di- and triglycoside bioflavonoids that contain an aglycone quercetin.

16. (Previously Added) A pharmaceutical composition comprising a composition according to claim 1 and one or more pharmaceutically acceptable excipients or auxiliaries.

17. (Previously Added) A pharmaceutical composition according to claim 16 that is lyophilized.

18. (Previously Added) A composition according to claim 1, wherein the molar ratio of components A:B:C is 20,000:1:10,000 to 500:1:100.

19. (Previously Added) A composition according to claim 1, wherein component A comprises one or more compounds selected from the group consisting of betaine, dimethylglycine, sarcosine and serine, and their physiologically acceptable salts, component B comprises one or more compounds selected from the group consisting of dihydrofolic acid, tetrahydrofolic acid, 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid, 10-formyltetrahydrofolic acid, 5,10-methylenetetrahydrofolic acid, and 5,10-methenyltetrahydrofolic acid, and their physiologically acceptable salts, and component C comprises one or more compounds selected from the group consisting of mono-, di- and triglycoside bioflavonoids that contain an aglycone quercetin.

20. (Currently cancelled without prejudice or disclaimer)

21. (Previously Added) A composition according to claim 1, wherein component B comprises one or more compounds selected from the group consisting of (6S)-tetrahydrofolic acid; 5-methyl-(6S)-tetrahydrofolic acid; 5-formyl-(6S)-tetrahydrofolic acid; 10-formyl-(6R)-tetrahydrofolic acid; 5,10-methylene-(6R)-tetrahydrofolic acid; 5,10-methenyl-(6R)-tetrahydrofolic acid; and their physiologically acceptable salts.

22. (Previously Added) A composition according to claim 1, wherein component B comprises one or more compounds selected from the group consisting of derivatives of L- and S-glutamic acid.

23. (Previously Added) A composition according to claim 1, wherein component B comprises 5-methyl-(6S)-tetrahydrofolic acid.

24. (Previously Added) A method of treating a transmethylation disorder

comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

25. (Previously Added) A method of treating a cardiovascular disease comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

26. (Previously Added) A method of treating an atherogenic and/or thrombogenic disease comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

27. (Previously Added) A method of treating a disease associated with hyperhomocysteinemia comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

28. (Previously Added) A method of treating premature occlusive arterial disease, severe vascular disease in infancy and childhood, progressive arterial stenosis, intermittent claudication, renovascular hypertension, ischemic cerebrovascular disease, premature retinal artery and retinal vein occlusion, cerebral occlusive arterial disease, occlusive peripheral arterial disease, premature death due to thromboembolic disease and/or ischemic heart disease, comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.